(Q37287033)

English

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

scientific article published on 08 June 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

object named as

Brandon Smith

4

0 references

object named as

Andrew J Vickers

9

0 references

object named as

Hans Lilja

10

0 references

author name string

Matthew Frank O'Brien

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Angel M Cronin

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Paul A Fearn

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jason Stasi

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bertrand Guillonneau

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter T Scardino

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

James A Eastham

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

8 June 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

22

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3591-3597

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

6 September 2017

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

14 September 2017

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

14 September 2017

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

14 September 2017

Critical analysis of prostate-specific antigen doubling time calculation methodology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

14 September 2017

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

3 September 2018

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

3 September 2018

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

3 September 2018

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720078

3 December 2018

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Methods for Calculating Prostate Specific Antigen Velocity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does PSA velocity predict prostate cancer in pre-screened populations?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/19506163

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.9794

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37287033&oldid=1667440320"